MedPath
HSA Product

STILAMIN 3000 FOR INJECTION 3 mg/ampoule

Product approved by Health Sciences Authority (SG)

Basic Information

STILAMIN 3000 FOR INJECTION 3 mg/ampoule

INJECTION, POWDER, FOR SOLUTION

Regulatory Information

SIN06135P

June 17, 1991

Prescription Only

Therapeutic

INTRAVENOUS

August 10, 2023

June 3, 2025

XH01CB01

Company Information

MERCK PTE. LTD.

MERCK PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**Contraindications** - Known hypersensitivity to somatostatin or any of the excipients of Stilamin® - During pregnancy and the immediate post- partum period (puerperium) as well as during lactation. There is no evidence of the drug’s safety in human pregnancy nor is there evidence from animal work that is free from hazard. Avoid in pregnancy unless there is no safer alternative.

Indication Information

**Indications and use** Stilamin® is indicated for: - Severe acute haemorrhage from oesophageal varices. - Severe acute haemorrhage from gastric or duodenal ulcers, or accompanying acute erosive or haemorrhagic gastritis. - Adjuvant treatment in pancreatic, biliary and intestinal fistulae. - Prophylaxis and treatment of postoperative complications following pancreatic surgery. - Adjuvant treatment in diabetic ketoacidosis.

© Copyright 2025. All Rights Reserved by MedPath